(Reuters) -Chinese biotechnology giant WuXi Apptec will raise HK$7.70 billion ($980.93 million) through share placement, in a ...

WuXi XDC cited strong demand for antibody-drug conjugates, which are widely used in targeted cancer treatments, and for ...

A solid run for Hong Kong stocks showed signs of cracking, as the city’s benchmark headed for a two-week low after the US ...

WuXi AppTec, China's leading CXO, is trading at a price-to-earnings (P/E) ratio of 21 times, much lower than the 30 times for Asymchem Laboratories (6821.HK). That differential, despite WuXi AppTec's ...

Innovative modular design will accelerate construction and manufacturing timelines, enabling rapid adaptation of manufacturing capacities across diverse product formats.Finished building will ...

SHANGHAI, June 18 (Reuters) - Drug research and development firms in China including WuXi AppTec (603259.SS), opens new tab and WuXi Biologics (2269.HK), opens new tab are changing project plans ...

CHENGDU, China, June 9, 2025 /PRNewswire/ -- WuXi Biologics (2269.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO), today announced that it has kicked ...

Wuxi Apptec said on Thursday it will be raising HK$7.70 billion ($980.98 million) through a share placement to aid its global ...